Clarithromycin had high efficacy in treatment of 39 community acquired pneumonia with low risk factors, including pneumonia 38 patients (50.67%), exacerbation of COPD and asthma 24 patients (32%), and acute bronchitis due to bacteria 13 patients (17.33%), with succesfully rate of 95.65%. The average duration of therapy was 8.56 days and only a few side effects (5.8%), including mainly nausea and diarrhea were observed. Clarithromycin is a safe and effective drug in treatment of community acquired lower respiratory infections
Pneumonia ; Clarithromycin ; Therapeutics ; Pharmaceutical Preparations ; Community-Acquired Infections